**Off Market Drug**
This medication is no longer available in the United States. Information provided here is for reference purposes only.
Inhibits metalloproteinase which prevents lice eggs from hatching.
Eradication of head lice.
Absorption: Some systemic absorption occurs following topical administration.
Protein Binding: Abametapir– 92%; Abametapir carboxyl– 97%.
Metabolism and Excretion: Primarily metabolized by the liver by the CYP1A2 isoenzyme to an active metabolite, abametapir carboxyl. Excretion pathyway unknown.
Half-life: Abametapir carboxyl– 31–111 hr.
TIME/ACTION PROFILE (eradication of head lice)
|Topical||unknown||24 hr||2 wk|
- Pedi: Children <6 mo (↑ risk of benzyl alcohol absorption; benzyl alcohol may be associated with "gasping syndrome" in neonates and low birth weight infants.
Use Cautiously in:
- OB: Safety not established;
- Lactation: Safety not established.
Adverse Reactions/Side Effects
Derm: burning sensation, contact dermatitis, erythema, hair color changes, pruritus, rash
EENT: eye irritation
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
May ↑ levels and risk of toxicity of CYP1A2 substrates, CYP2B6 substrates, and CYP3A4 substrates ; avoid use of these medications within 2 wk of abemetapir administration.
Topical (Adults and Children ≥6 mo): Apply amount necessary to coat hair and scalp (up to 1 bottle), message thoroughly, leave in place for 10 minutes, then rinse with warm water.
Topical lotion (contains benzyl alcohol): 0.74%
- Activity intolerance
To view other topics, please log in or purchase a subscription.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. Complete Product Information.